Screener
Neurocrine Biosciences NBIX Net debt / EBITDA
Net debt / EBITDA at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on the most recent quarter.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
FAQ
- What is Neurocrine Biosciences's net debt / EBITDA?
- Neurocrine Biosciences (NBIX) reported net debt / EBITDA of 0.2× in Q1 2026.
- How has Neurocrine Biosciences's net debt / EBITDA changed year-over-year?
- Neurocrine Biosciences's net debt / EBITDA decreased by 58.5% year-over-year, from 0.6× to 0.2×.
- What is the long-term trend for Neurocrine Biosciences's net debt / EBITDA?
- Over 4 years (2020 to 2025), Neurocrine Biosciences's net debt / EBITDA has grown at a -6.3% compound annual growth rate (CAGR), from -0.5× to -0.4×.
- What does net debt / EBITDA mean?
- Net debt (total debt minus cash) divided by trailing-twelve-month EBITDA. Expresses leverage in years — roughly how long it would take to repay net debt out of operating cash earnings.
Ask your AI about Neurocrine Biosciences's net debt / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude